TY - JOUR T1 - Preliminary data on precision of QuantiFERON-TB Plus performance JF - European Respiratory Journal JO - Eur Respir J SP - 955 LP - 956 DO - 10.1183/13993003.01084-2016 VL - 48 IS - 3 AU - Daniela Maria Cirillo AU - Lucia Barcellini AU - Delia Goletti Y1 - 2016/09/01 UR - http://erj.ersjournals.com/content/48/3/955.abstract N2 - We agree with D. Gallagher and colleagues on the need to corroborate our recently published preliminary findings with larger and well-designed studies targeting different risk groups and performed in settings with low and high burdens of tuberculosis (TB). Indeed, we do hope that our first assessment of the QuantiFERON-TB Plus (QFT-Plus) (QIAGEN GmbH, Hilden, Germany) performance characteristics, together with the data presented by D. Gallagher and colleagues, may constitute the first body of evidence necessary to guide clinical and programmatic use of QFT-Plus within the context of TB infection management and TB elimination strategy [1].Variability of QFT-Plus response still needs to be determined with large studies to establish appropriate cut-offs http://ow.ly/60bP301kLRT ER -